|
Headlines:
|
 |
Non-Hodgkin's Lymphoma
Staging and prognostic factors
| |
Non-Hodgkin's Lymphoma News |
| |
 |
| |
|
| |
|
| |
|
| |
Non-Hodgkin's Lymphoma |
| |
|
| |
|
Staging techniques -
Supradiaphragmatic involvement
Chest x-ray
(mediastinal or hilar adenopathy, pleural effusions,
parenchymal lesions) the chest radiograph is abnormal in fewer than 50% of patients,
identification of hilar or mediastinal adenopathy, parenchymal
lesions, or pleural effusions is important and provides an easy
method for reevaluation.
CT scan of the chest
(mediastinal, hilar, or parenchymal pulmonary
disease)
Subdiaphragmatic involvement
CT scan
CT scan of the abdomen and pelvis is essential in staging of
lymphoma (enlarged lymph nodes,
splenomegaly,
filling defects in liver and spleen)
- CT scan has a sensitivity of 80% and a specificity of 70% in
detection of lymphoma.
PET
PET (FDG-glucose) scanning is gaining wider acceptance as a
potential
diagnostic approach for staging at diagnosis, response assessment,
and
relapse.
Hematologic involvement
CBC
CBC with differential and platelet count (peripheral blood
lymphocytosis
with circulating malignant cells is common in low-grade and mantle
cell lymphomas). Bone marrow and peripheral blood involvement may
be present, and the distinction between leukemia and lymphoma is
difficult
to make in some cases.
Bilateral bone marrow biopsy
Unilateral percutaneous
bone marrow biopsies must be performed,
because the likelihood of lymphomatous involvement of the marrow is relatively high, especially in
most indolent lymphomas, in which marrow
involvement occurs in as high as 40% to 90% of
cases.
Extranodal evaluation
Endoscopy
Upper GI endoscopy and/or GI series with small bowel
follow-through
in patients with head and neck involvement (tonsil, base of tongue, nasopharynx)
and those with a GI primary; mantle- cell lymphoma is associated
with a high incidence of occult GI involvement.
Ultrasonography
Ultrasonography of opposite testis in patients with a testicular
primary.
CNS involvement
CSF examination
Perform examination of CSF and strongly consider CNS prophylaxis
in patients with
- Diffuse aggressive NHL with bone marrow,
epidural,
testicular, paranasal sinus, or nasopharyngeal involvement
- Highgrade
lymphoblastic lymphoma and Burkitt lymphoma and its variants
- HIV-related lymphoma
- Primary CNS lymphoma if no evidence of increased
intracranial pressure
- Lymphoma
related
to immunosuppression after solid-organ transplant (ie, liver, lungs,
and kidneys)
General chemistry panel (lactic dehydrogenase [LDH] level
determination)
is mandatory; β2
-microglobulin (β2M) is recommended.
Spinal MRI scan
Spinal MRI scan for epidural disease when clinically indicated
(useful in the evaluation of suspected spinal cord compression).
HIV serology
HIV serology in at-risk patients with diffuse large cell, and
other
aggressive and Burkitt histologies; HTLV-1 serology in select
patients
with cutaneous T-cell lymphoma, especially if they have
hypercalcemia. Staging of Non-Hodgkin's Lymphoma

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
Prognostic factors
The NHLs can be divided into 2 prognostic groups: the indolent
lymphomas and the aggressive lymphomas.
Indolent NHL
Indolent NHL types have a relatively good prognosis, with median
survival as long as 10 years, but they usually are not curable in
advanced clinical stages.
An international index for follicular lymphoma (i.e., the
Follicular Lymphoma International Prognostic Index [FLIPI])
identified 5 significant risk factors prognostic of overall
survival:
- Age (≤ 60 years vs. > 60 years).
- Serum lactate dehydrogenase (normal vs. elevated).
- Stage (stage I or stage II vs. stage III or stage IV).
- Hemoglobin level (≥ 120 g/L vs. < 120 g/L).
- Number of nodal areas (≤ 4 vs. > 4).
Patients with 0 to 1 risk factors have an 85% 10-year survival
rate, while 3 or more risk factors confer a 40% 10-year survival
rate.
There are several other prognostic index models for the low-
grade lymphomas. Unfavorable prognostic factors include extent of
bone marrow involvement (> 20%), bulky disease (≥ 5-7 cm), more than
one extranodal site, LDH level > 1 times normal values, elevated β2M,
and nonambulatory performance status.
Aggressive type NHL
The aggressive type of NHL has a relatively poor prognosis and
shorter natural history, but a significant number of these patients
can be cured with intensive combination chemotherapy regimens.
An International Prognostic Index (IPI) for aggressive NHL
(diffuse large cell lymphoma) identifies 5 significant risk factors
prognostic of overall survival:
- Age (≤60 years of age vs. >60 years of age).
- Serum lactate dehydrogenase (normal vs. elevated).
- Stage (stage I or stage II vs. stage III or stage IV).
- Performance status (0 or 1 vs. 2-4).
- Extranodal site involvement (0 or 1 vs. 2-4).
Patients with 2 or more risk factors have a <50% chance of
relapse-free and overall survival at 5 years. This study also
identifies patients at high risk of relapse based on specific sites
of involvement, including bone marrow, central nervous system (CNS),
liver, lung, and spleen. Age-adjusted and stage-adjusted
modifications of this IPI are used for younger patients with
localized disease.
|